Venus Remedies Limited has informed the Exchange regarding 'Venus Remedies Secures Ukrainian GMP Renewal, Strengthening Global Pharmaceutical Presence'.
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Venus Remedies has renewed its Good Manufacturing Practices (GMP) certification from Ukraine's State Service on Medicines and Drugs Control for its Baddi Unit-II facility in Himachal Pradesh. The certification covers the company's cephalosporin, carbapenem, and oncology parenteral production lines, including liquid and lyophilized injections. As Ukraine is part of the PIC/S consortium of 56 countries, this renewal strengthens Venus Remedies' foothold in the Ukrainian market and opens doors to broader PIC/S markets. The company has 20+ years of presence in Ukraine, 44 product registrations, and already operates in 32 PIC/S countries.
This regulatory renewal supports continued exports to Ukraine (a market projected to reach US$822 million by 2029) and other PIC/S countries, which is positive for international revenue. However, the announcement is a certification renewal rather than a new order or contract win, so the direct stock price impact may be limited.